van der Straten A, Gómez C A, Saul J, Quan J, Padian N
Center for AIDS Prevention Studies, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 94105, USA.
AIDS. 2000 Mar 10;14(4):F47-54. doi: 10.1097/00002030-200003100-00003.
To describe awareness and use of antiretroviral treatments, viral load monitoring, and post-exposure prevention; to assess changing concerns about HIV transmission; and to examine the effect of these advances on sexual behavior in HIV-serodiscordant heterosexual couples.
Cross-sectional analysis of a baseline sample of 104 couples (n = 208 individuals) from the California Partners Study II, an intervention trial for HIV-serodiscordant couples in California. Questions on sexual practices, viral load testing, HIV treatment, post-exposure prevention, and their effect on sexual behaviors, risk taking and transmission concerns were measured at intake.
Over two-thirds of couple members surveyed reported unprotected sex with their partner in the past 6 months. Among seropositive respondents, 37% were taking protease inhibitor therapy, 92% had undergone viral load testing, and of those, 40% said it had ben undetectable at their most recent test. Most respondents, regardless of serostatus, said that viral load testing and awareness of post-exposure prevention had no effect on their condom use. In addition, perceiving that their partner had an undetectable viral load was associated with having protected sex among seronegative subjects (P < 0.05). Seropositive respondent taking protease inhibitors were 2.4 times less likely to report unprotected sex compared with those not taking protease inhibitors (P = 0.05). However, up to 33% of seropositive and 40% of seronegative respondents acknowledged decreased transmission concerns in the light of the new HIV treatments. In comparison with their seropositive partners, seronegative individuals were more likely to acknowledge increased risk taking and decreased HIV transmission concerns (P < 0.05).
New medical advances were not associated with unprotected sex in HIV-serodiscordant couples. However, new treatment options may decrease concerns about HIV transmission, particularly among seronegative partners. Providers should discuss the effect of antiretroviral treatments on sexual transmission risk with their patients. The inclusion of seronegative partners in counseling interventions may decrease risk taking in serodiscordant couples.
描述抗逆转录病毒治疗、病毒载量监测及暴露后预防的知晓率和使用率;评估对HIV传播的担忧变化;并研究这些进展对HIV血清学不一致的异性恋伴侣性行为的影响。
对来自加利福尼亚伴侣研究II的104对夫妇(n = 208人)的基线样本进行横断面分析,该研究是加利福尼亚针对HIV血清学不一致夫妇的一项干预试验。在入组时测量关于性行为、病毒载量检测、HIV治疗、暴露后预防及其对性行为、冒险行为和传播担忧的影响的问题。
超过三分之二接受调查的夫妇成员报告在过去6个月与伴侣有无保护性行为。在血清阳性受访者中,37%正在接受蛋白酶抑制剂治疗,92%接受过病毒载量检测,其中40%表示在最近一次检测中病毒载量不可检测。大多数受访者,无论血清学状态如何,均表示病毒载量检测和暴露后预防的知晓对其使用避孕套没有影响。此外,血清阴性受试者中,认为伴侣病毒载量不可检测与进行保护性行为相关(P < 0.05)。与未服用蛋白酶抑制剂的血清阳性受访者相比,服用蛋白酶抑制剂的血清阳性受访者报告无保护性行为的可能性低2.4倍(P = 0.05)。然而,高达33%的血清阳性和40%的血清阴性受访者承认鉴于新的HIV治疗,对传播的担忧有所降低。与血清阳性伴侣相比,血清阴性个体更有可能承认冒险行为增加和对HIV传播的担忧降低(P < 0.05)。
新的医学进展与HIV血清学不一致夫妇的无保护性行为无关。然而,新的治疗选择可能会降低对HIV传播的担忧,尤其是在血清阴性伴侣中。医疗服务提供者应与患者讨论抗逆转录病毒治疗对性传播风险的影响。将血清阴性伴侣纳入咨询干预可能会降低血清学不一致夫妇的冒险行为。